[ESPR] Esperion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 13.18 Change: 0.52 (4.11%)
Ext. hours: Change: 0 (0%)

chart ESPR

Refresh chart

Strongest Trends Summary For ESPR

ESPR is in the medium-term down -33% below S&P in 6 months. In the long-term down -37% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase IIb clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic apoA-I therapy that is in pre-clinical trials for treating patients with acute coronary syndrome. The company is headquartered in Plymouth, Michigan.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-12.29% ROE-12.71% ROI
Current Ratio40.33 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities190.41 M Cash From Investing Activities-57.55 M Cash From Operating Activities-9.26 M Gross Profit
Net Profit-11.47 M Operating Profit-11.43 M Total Assets325.22 M Total Current Assets279.83 M
Total Current Liabilities6.94 M Total Debt4.88 M Total Liabilities10.79 M Total Revenue
Technical Data
High 52 week59.11 Low 52 week36.99 Last close37.71 Last change-3.36%
RSI22.75 Average true range1.65 Beta1.81 Volume98.17 K
Simple moving average 20 days-8.5% Simple moving average 50 days-17.36% Simple moving average 200 days-18.33%
Performance Data
Performance Week-2.48% Performance Month-19.34% Performance Quart-24.84% Performance Half-16.7%
Performance Year-18.66% Performance Year-to-date-18.02% Volatility daily1.86% Volatility weekly4.15%
Volatility monthly8.51% Volatility yearly29.48% Relative Volume258.64% Average Volume447.01 K
New High New Low

News

2019-12-06 11:31:04 | Esperion Therapeutics ESPR Up 25.1% Since Last Earnings Report: Can It Continue?

2019-11-28 07:09:12 | Esperion's Promising Drugs Under Review, Funds a Concern

2019-11-22 18:30:10 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-11-19 09:13:02 | Esperion Therapeutics ESPR Catches Eye: Stock Jumps 10%

2019-11-17 15:05:00 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

2019-11-12 11:05:00 | Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

2019-11-10 07:56:48 | President Timothy Mayleben Just Bought Shares In Esperion Therapeutics, Inc. NASDAQ:ESPR

2019-11-09 09:26:54 | Is Esperion Therapeutics's NASDAQ:ESPR Share Price Gain Of 215% Well Earned?

2019-11-07 11:04:04 | Esperion ESPR Reports Wider-Than-Expected Loss in Q3

2019-11-07 07:30:00 | Esperion to Participate in Upcoming Investor Conferences

2019-11-06 08:45:01 | Esperion Therapeutics ESPR Reports Q3 Loss, Tops Revenue Estimates

2019-11-06 07:30:00 | Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

2019-11-04 07:30:00 | Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

2019-10-29 07:30:05 | Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

2019-10-28 17:15:57 | Should You Buy Esperion Therapeutics, Inc. ESPR?

2019-10-25 10:00:05 | Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

2019-10-04 08:34:48 | Here's Why We're Not At All Concerned With Esperion Therapeutics's NASDAQ:ESPR Cash Burn Situation

2019-09-09 10:57:53 | 7 Micro-Cap and Small-Cap Stocks That Insiders Are Buying

2019-09-07 09:30:01 | Esperion Therapeutics ESPR Down 10.8% Since Last Earnings Report: Can It Rebound?

2019-09-06 18:15:05 | Esperion Therapeutics Inc ESPR President & CEO Timothy M Mayleben Bought $259,125 of Shares

2019-08-30 16:15:00 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-08-30 10:26:02 | Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study

2019-08-29 07:30:00 | Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

2019-08-26 11:05:03 | Esperion's Drugs in Review Hold Potential, Funds a Concern

2019-08-20 11:15:21 | Does Market Volatility Impact Esperion Therapeutics, Inc.'s NASDAQ:ESPR Share Price?

2019-08-09 08:06:12 | Esperion ESPR Q2 Loss Wider Than Expected, Revenues Beat

2019-08-08 09:15:01 | Esperion Therapeutics ESPR Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 07:30:00 | Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

2019-08-06 16:15:00 | Esperion to Present at the BTIG Biotechnology Conference

2019-08-02 19:15:18 | Esperion Therapeutics Inc ESPR President & CEO Timothy M Mayleben Bought $197,800 of Shares

2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma

2019-07-30 16:15:00 | Esperion to Report Second Quarter 2019 Financial Results August 8, 2019

2019-07-30 15:16:07 | A Firm's First Profit Can Mean Big Returns for Investors

2019-07-29 08:08:39 | 3 Biotech Stocks Corporate Insiders are Buying

2019-07-07 19:10:32 | Weekly CEO Buys Highlight

2019-07-05 12:25:51 | Is Esperion Therapeutics, Inc. ESPR A Good Stock To Buy?

2019-06-26 16:10:00 | Esperion and Oberland Capital Announce $200 Million Funding Agreement

2019-06-19 10:40:19 | Have Insiders Been Buying Esperion Therapeutics, Inc. NASDAQ:ESPR Shares This Year?

2019-06-07 09:30:01 | Esperion Therapeutics ESPR Down 5.6% Since Last Earnings Report: Can It Rebound?

2019-05-30 16:15:00 | Esperion Announces the Appointment of Tracy M. Woody to Board of Directors

2019-05-29 16:23:31 | Biotech Stocks Clobbered As Two Slammed With Sell Ratings

2019-05-28 07:00:00 | Esperion to Participate in Upcoming Investor Conferences

2019-05-27 06:00:00 | Esperion Aims for the First Approved Non-Statin Cholesterol Reducer

2019-05-10 08:00:00 | Esperion to Participate in Upcoming Investor Conferences

2019-05-09 06:00:00 | Esperion Gets a Go-Ahead from the FDA

2019-05-08 08:35:12 | Esperion Therapeutics ESPR Q1 Earnings and Revenues Surpass Estimates

2019-05-08 07:25:22 | Esperion Therapeutics: 1Q Earnings Snapshot

2019-05-08 07:00:00 | Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results

2019-05-07 05:30:00 | Esperion to Host Analyst and Investor Day Event on May 30

2019-05-06 16:15:57 | A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why